Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03147989 · ClinicalTrials.gov registry record
Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients
A clinical trial, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- 352
- Enrollment target
NCT03147989 is a clinical trial that has completed, run by Bracco Diagnostics. The registered enrollment target is 352 participants.
The verdict
NCT03147989 has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- 352 participants
- Enrollment target
Study Summary
This is a retrospective study to collect already existing data and images from patients ≥ 2 years of age who had MRI for CNS diseases with MultiHance administration at a standard 0.10 mmol/kg dose or the half dose of 0.05 mmol/kg. The MRI images of all included patients will be prospectively reviewed in a blinded read to compare the efficacy of the two doses.
Interventions
- DRUG MultiHance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2017-05-18 |
| Est. Completion | 2018-03-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03147989
The ClinicalTrials.gov registry entry for NCT03147989 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 352 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MultiHance is the first listed.
NCT03147989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03147989 about?
NCT03147989 is a clinical study titled "Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients". This is a retrospective study to collect already existing data and images from patients ≥ 2 years of age who had MRI for CNS diseases with MultiHance administration at a standard 0.10 mmol/kg dose or the half dose of 0.05 mmol/kg. The MRI images of all included patients will be prospectively reviewe...
What is the current status of trial NCT03147989?
This trial is currently completed. The enrollment target is 352 participants. The study started on 2017-05-18. Estimated completion is 2018-03-16.
What interventions are being tested in trial NCT03147989?
The interventions under investigation include: MultiHance (DRUG).
Who is sponsoring clinical trial NCT03147989?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.